Evidence map›Paper›PMID 39640887›Full record

ArticleFrontiers in endocrinology2024

Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials.

Shihui Hu, Yannan Zhao, Yizhao Xie, Shuhui You, Xichun Hu, Jian Zhang, Leiping Wang, Jun Cao, Chengcheng Gong, Biyun Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shihui HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yannan ZhaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yizhao XieDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Shuhui YouDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xichun HuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jian ZhangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Leiping WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Jun CaoDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Chengcheng GongDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Biyun WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: With the approval of trastuzumab deruxtecan for the treatment of unresectable/metastatic HER2-low breast cancer, human epidermal growth factor receptor 2 (HER2)-low has emerged as a clinically actionable biomarker. There is an urgent need for a deeper understanding of HER2-low breast cancer patients. Therefore, this study was conducted to explore the clinicopathological characteristics, the evolution of HER2-low status, and its impact on the prognosis of hormone receptor (HoR)-negative/HER2-low metastatic breast cancer (MBC) patients. Methods: This pooled analysis included 350 metastatic triple-negative breast cancer (mTNBC) patients who received first-line platinum-based chemotherapy at Fudan University Shanghai Cancer Center from November 2007 to July 2022. Patients were categorized into HER2-0 and HER2-low groups based on their HER2 status. Baseline clinicopathological characteristics, evolution of HER2 status between primary and metastatic lesions, and treatment efficacy were compared between the two groups. Results: Among the 350 mTNBC patients, 34.9% (122/350) were HER2-low and 65.1% (228/350) were HER2-0. Significant differences were observed between HER2-low and HER2-0 patients in terms of age and menopausal status. HER2-low patients were older (54 Conclusion: In mTNBC patients, those with HER2-low status had similar responses to platinum-based chemotherapy as HER2-0 patients. There was significant discordance in HER2 status between primary and metastatic lesions. Patients with discordant HER2 status had better responses to platinum-based chemotherapy. Therefore, for patients with HER2-0 primary lesions, re-evaluation of HER2 status in metastatic lesions through biopsy may offer new treatment opportunities.

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorFemaleHumansMiddle AgedNeoplasm MetastasisPrognosisProspective StudiesReceptors, EstrogenReceptors, ProgesteroneTrastuzumabTreatment OutcomeBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneTrastuzumabchemotherapyChinese womenevolutionHER2-lowhormone receptor-negativemetastatic breast cancer

Identifiers

PMID39640887
PMCPMC11617163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.